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Abstract Recently, magnetic nanoparticles of iron oxide
(Fe3O4, c-Fe2O3) have shown an increasing number of
applications in the ﬁeld of biomedicine, but some questions
have been raised about the potential impact of these
nanoparticles on the environment and human health. In this
work, the three types of magnetic nanoparticles (DMSA-
Fe2O3, APTS-Fe2O3, and GLU-Fe2O3) with the same
crystal structure, magnetic properties, and size distribution
was designed, prepared, and characterized by transmission
electronic microscopy, powder X-ray diffraction, zeta
potential analyzer, vibrating sample magnetometer, and
Fourier transform Infrared spectroscopy. Then, we have
investigated the effect of the three types of magnetic
nanoparticles (DMSA-Fe2O3, APTS-Fe2O3, and GLU-
Fe2O3) on smooth muscle cells (SMCs). Cellular uptake of
nanoparticles by SMC displays the dose, the incubation
time and surface property dependent patterns. Through the
thin section TEM images, we observe that DMSA-Fe2O3 is
incorporated into the lysosome of SMCs. The magnetic
nanoparticles have no inﬂammation impact, but decrease
the viability of SMCs. The other questions about
metabolism and other impacts will be the next subject of
further studies.
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Introduction
Magnetic nanomaterial has shown an increasing number of
applications in different ﬁelds of information, mechanics,
and biomedicine due to their multifunctional properties
such as small size effect, superparamagnetism, inherently
biocompatibility, etc. [1–4]. Especially in the last decade,
the ﬁeld of biomedicine witnessed an explosion of interest
in the use of magnetic nanomaterial in earlier diagnosis and
effective treatment of some diseases, such as magnetic
resonance imaging (MRI) [5, 6], drug delivery [7–11],
hyperthermia, etc. [12, 13]. In MRI, magnetic nanoparticles
serve as contrast enhancement agents, in drug delivery,
they function as drug carriers delivering and releasing the
drug into target cells, while in hyperthermia, they serve as
generator of heat under alternating current magnetic ﬁeld.
In certain cases, the employment based on magnetic
nanomaterial has displayed signiﬁcant advantages over
conventional material with regard to assay sensitivity,
effect of treatment, side effect, etc.
In biological applications, the current magnetic nano-
particles (MNPs) of iron oxide (Fe3O4, c-Fe2O3) may be
modest and biocompatible [14, 15], but some questions
have been raised about the potential impact of these
nanoparticles on the environment and human health.
Numerous investigations have been carried out using iron
oxides nanoparticles linked to their high mobility and
speciﬁc reactivity with cells. Some results indicate that iron
Song Zhang and Xiangjian Chen contributed equally to this work.
S. Zhang  Y. Zhang  N. Gu (&)
State Key Laboratory of Molecule and Biomolecule Electronics,
Jiangsu Provincial Laboratory for Biomaterials and Devices,
Southeast University, 210096 Nanjing,
People’s Republic of China
e-mail: guning@seu.edu.cn
X. Chen  C. Gu  J. Xu  Z. Bian  D. Yang (&)
Institute of Cardiovascular Disease, The First Afﬁliated Hospital
of Nanjing Medical University, 210029 Nanjing,
People’s Republic of China
e-mail: dyang@public1.ptt.js.cn
123
Nanoscale Res Lett (2009) 4:70–77
DOI 10.1007/s11671-008-9204-7oxide nanoparticles could be internalized by cells and
induce a dramatic decrease in the metabolic activity and
proliferation of human cells (MSTO-211H) [16–20]. A
quantiﬁable model cell system shows that intracellular
delivery of even moderate levels of iron oxide (Fe2O3)
nanoparticles may adversely affect cell function. More
speciﬁcally, the cytotoxicity studies show that exposure to
increasing concentrations of anionic MNPs, from 0.15 to
15 mM of iron, results in a dose-dependent diminishing
viability and capacity of PC12 cells to extend neurites in
response to nerve growth factor [21].
Recently, the cytotoxicity assessment about iron oxide
nanoparticles has been focused on by more and more
researchers. Nevertheless, as mentioned by Auffan et al.
[16], toxicological data are difﬁcult to compare since the
parameters controlled in each of these studies may differ.
These parameters involve size distribution, surface prop-
erties, magnetic properties, stability in biological media,
etc. In this present study, the aim is to elucidate the effect
of different iron oxide magnetic nanoparticles (c-Fe2O3,
MNPs) on Sprague-Dawley rat smooth muscle cell (SMC)
in vitro. In particularly, MNPs were coated by meso-2,
3-dimercaptosuccinic acid (DMSA), 3-amino-propyltri-
ethoxysilane (APTS), and L-glutamic acid (GLU),
respectively, but possess the same size distribution and
magnetic properties and stability, which can ensure the
consistence and comparability of investigation results.
Experimental Section
Reagents
Magnetic nanoparticles were synthesized, and stored in
the dark at 4 C. Dulbecco’s modiﬁed Eagle’s medium
(DMEM) was purchased from GIBCO Company. Penicillin
and streptomycin were purchased SIGMA Company. TNF-
a ELISA Kit was purchased from BOSTER Company. All
of other chemicals were of reagent grade and were used as
received without further puriﬁcation. Double distilled
water was used for all the experiments.
Preparation of the Coated MNPs
Fe3O4 nanoparticles were synthesized by chemical copre-
cipitation of Molday [22]. Typically, a solution of mixture
of FeCl3 and FeSO4 (molar ratio 2:1) was prepared under
N2 protecting, followed by the slow addition of enough
ammonia aqueous solution with vigorous stirring for
30 min. The black Fe3O4 precipitates were obtained and
washed immediately with distilled water for ﬁve times by
magnetic separation. The ﬁnal precipitates were dispersed
in distilled water with concentration of 0.128 M and pH
3.0, and oxidized into more stable MNPs (c-Fe2O3) by air
at the temperature of 90 C.
According to the process described in the literature [23,
24], MNPs were coated with DMSA and GLU. Finally
stable aqueous sol DMSA-MNPs (DMSA-Fe2O3), and
GLU-MNPs (GLU-Fe2O3) were obtained. Similarly,
APTS-MNPs (APTS-Fe2O3) were prepared according to
literature [25]. The part of above samples was dried into
powder at room temperature under vacuum.
Characterization
The particle size and morphology of the coated MNPs was
determined by transmission electronic microscopy (TEM,
JEOL, JEM-200EX). Powder X-ray diffraction (XRD,
Rigaku, D/Max-RA, k = 1.5405 9 10
-10 m, CuK) was
used to determine the crystal structure of MNPs. Surface
charge measurements were performed with a zeta potential
analyzer (BECKMAN, Delsa 440SX). The magnetic
measurements were carried out with a vibrating sample
magnetometer (VSM, Lakeshore 7407). Fourier transform
infrared (FTIR) spectroscopy measurements were per-
formed on a Bruker Fourier transform spectrometer model
VECTOR22 using KBr pressed discs.
Cell Culture
Sprague-Dawley (SD) rat aortic SMCs were grown from
explants of normal SD rat aorta fragments. Cells were
further cultured in Dulbecco’s modiﬁed Eagle medium
(DMEM) containing 15% fetal bovine serum (FBS), pen-
icillin (100 lg/mL), and streptomycin (100 lg/mL), in 5%
CO2 chamber.
Incubation of SMC with the Coated MNPs
All the coated MNPs was sterilized with ﬁlter-ﬁlm (pore
size, 0.22 lm) and sonicated before dilution into DMEM
culture medium to ensure even particle suspension. Then,
the MNPs were diluted with DMEM at different concen-
tration and added into the plates in triplicate for a further
speciﬁed time after the normal medium was removed. All
control cells were cultured in the absence of any particles.
Every experiment was repeated at least three times
independently.
Cellular Uptake of MNPs Assay
Cellular uptake of MNPs was evaluated according to the
method of Petri-Fink [26]. The supernate of cells on the 6-
well plates was removed and cells were thoroughly washed
with PBS and resuspended in 2 M HCl (1 mL/well of a 6-
well plate) at 37 C for 2 h. The protein concentration of
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Spectrophotometer (UV–vis). 1 mL of 5% solution of
K4[Fe(CN)6]i nH 2O was added, and the absorbance of
samples was read after 10 min at 690 nm. A standard curve
of an aqueous FeCl3  6H2O solution was treated in the
same conditions to quantify the amount of cellular uptake of
MNPs. The cellular uptake of MNPs was expressed at the
amount of Fe2O3 (weight, lg) per milligram of protein.
TEM Analysis
The SMC incubated with DMSA-MNPs for 24 h were
washed with PBS and ﬁxed in 4% glutaraldehyde solution
for 1 h at 4 C. The cells were postﬁxed in 1% osmium
tetroxide for 1 h at room temperature and washed. Then,
cells were scraped and concentrated in 2.5% agar in
0.05 M cacodylate buffer. The obtained samples were then
treated with 2% uranyl acetate solution for 1 h and sub-
sequently dehydrated by means of ethanol/water solutions,
with increasing ethanol content and embedded in epoxy
resin [27]. The samples were cut at 70 nm (ultrathin sec-
tions) with an ultramicrotome. Ultrathin sections were
transferred to the 300 mesh copper grid and stained with
5% uranyl acetate. The copper grid was observed on a
transmission electron microscope (TEM, HITACHIH-600)
at 80 kV.
Fig. 1 The TEM image and
size distribution of
nanoparticles. a DMSA-MNPs,
b APTS-MNPs, and c GLU-
MNPs
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After incubation for a period of time, cell culture supernate
was collected and centrifuged at 8,0009g for 30 min to
remove cell debris and nanoparticles. Tumor necrosis factor
a (TNF-a) protein concentrations in the supernate were
measured using an ELISA kit (RAT TNF-a, ELISA KIT,
BOSTER) according to the manufacturer’s instructions.
Cell Viability Assay
Viability of SMC was determined by using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide)
assay. After incubation the supernate was removed and
200 lL MTT solution (0.5 mg/mL in DMEM medium) was
added at 37 C for 2 h. Then, cells were rinsed two times
with PBS and 150 lL extracting solution (0.04 M HCl in
isopropanol) was added to each well of 96-well plates. The
plates were placed for 15 min at ambient temperature to
dissolve the dyes and the dye extract was transferred to 96
well Elisa plates. Absorbance was assayed at 570 nm by
Ultra Microplate Reader ELX808 IU (Bio-Tek) and the cell
viability was expressed in percent based on the control.
Results and Discussion
Preparation of the Coated MNPs and Characterization
Magnetic nanoparticles were synthesized by chemical
coprecipitation and stable magnetic ﬂuid was obtained via
coating by DMSA, APTS, and GLU. The morphology and
Fig. 2 X-ray powder diffraction of the uncoated MNPs
Fig. 3 FTIR spectra of the uncoated MNPs, DMSA-MNPs, APTS-
MNPs, and GLU-MNPs
Fig. 4 pH-dependent zeta potential curves of DMSA-MNPs, APTS-
MNPs, and GLU-MNPs
Fig. 5 Magnetization versus applied magnetic ﬁeld for the coated
MNPs
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123structure of particles were observed by TEM, and the
images indicate that most of the particles are quasi-spher-
ical and with an average diameter of 10 nm. The TEM
image and size distribution of particles are shown in Fig. 1
The same morphology and size distribution can avoid the
difference of size effect. The phase identiﬁcation of the
uncoated MNPs was performed by XRD. As shown in
Fig. 2, the result shows that the MNPs are inverse cubic
spinel structure [28]. Compared with the theoretical values,
the reduction of d-spacing obtained experimentally is due
to the lattice constrictions for nanosized particles [25].
Fourier transform infrared spectroscopy was used to
conﬁrm that the DMSA, APTS, and GLU were success-
fully coated on the nanoparticles. The FTIR spectra of
MNPs, DMSA-MNPs, APTS-MNPs, and GLU-MNPs are
shown in Fig. 3 All samples show broad band at
3400 cm
-1 indicative of the presence of –OH groups on
nanoparticles surface. Compared with the uncoated MNPs,
all the coated MNPs possess absorption bands in 2956 and
2922 cm
-1 due to stretching vibration of C–H bond. In
addition, for DMSA-MNPs, the band in 1715 cm
-1
appears due to stretching vibration of C=O bond, which
reveals the existence of DMSA. For APTS-MNPs, bands in
1091 and 1051 cm
-1 are attributed to stretching vibration
of C–N bond and Si–O bond, band in 932 cm
-1 is attrib-
uted to bending vibration of –NH2. In the spectrum of
GLU-MNPs, the bands in 1091 and in 932 cm
-1 are also
observed because the existence of C–O and –NH2 group,
which is the strong evidence that GLU is bonded to the
surface of the nanoparticles.
Zeta (n) potential measurement as a function of pH has
been performed to conﬁrm the surface charge properties
and the presence of DMSA, APTS, and GLU on the surface
of MNPs. Figure 4 shows that the DMSA-MNPs have high
negative potential at the pH range, while the APTS and
GLU-MNPs are positively charged at lower pH and neg-
atively at higher pH and their isoelectric points (IEP) are
7.2 and 7.9, respectively. The difference of charge prop-
erties of them attribute to the ionization of the functional
groups, such as –COOH, –SH and –NH2 at different pH.
According to results, we can make sure that the surface
charge property is negative for DMSA-MNPs, positive for
APTS-MNPs, and nearly neutral for GLU-MNPs in the
physicochemical states (pH 7.4).
The magnetic property of the MNPs was measured by
VSM. Figure 5 shows the magnetization of the coated
MNPs as a function of an external ﬁeld at ambient tem-
perature. The three of MNPs possess similar magnetization
loops and saturation magnetization (50 emu/g) because of
Fig. 6 Cellular uptake of MNPs by smooth muscle cell (SMC). All
values are represented the mean ± standard deviation (SD) of three
experiments, each performed in triplicate. Control columns mean that
SMC was incubated with only DMEM. a SMC was incubated with
DMEM containing the indicated concentration of DMSA-MNPs for
24 h. b SMC was incubated with DMEM containing 0.1 mg/mL
DMSA-MNPs for the indicated incubation time, and c SMC was
incubated with DMEM containing 0.1 mg/mL indicated MNPs for
24 h
c
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123the same structure and size distribution. The synthesized
MNPs also show a superparamagnetic behavior, as evi-
denced by zero coercivity and remanance on the
magnetization loops.
Cellular Uptake of MNPs
The cellular uptake amount is counted based on the Fe2O3
per milligram protein that released from the cells. For the
DMSA-MNPs, the cellular uptake of MNPs by SMC
increases with increasing concentration from 0.001 to
0.5 mg/mL in DMEM, as shown in Fig. 6a. The uptake
also shows the same behavior with increasing of incubation
time from 24 to 72 h when the concentration of DMSA-
MNPs is 0.1 mg/mL (Fig. 6b). Brieﬂy, the cellular uptake
shows a clear dose and incubation time dependent patterns
under the experiment conditions.
The cellular uptake indicates a function of surface
properties of MNPs. From Fig. 6c, there is obvious dif-
ference among the three types of MNPs at the same
concentration (0.1 mg/mL) for the same incubation time
(24 h). The uptake amount of APTS-MNPs, GLU-MNPs,
and DMSA-MNPs are 3.72, 4.60, and 8.98 lg per milli-
gram protein, respectively. We infer that the different
surface properties, such as charges of surface molecules,
result in the different afﬁnity with SMC [27, 29–32].
According to the results, it is promising to facilitate or alter
uptake of SMC by altering the surface properties of MNPs.
Endocytosis of DMSA-MNPs by SMC
The thin section TEM images indicate that the DMSA-
MNPs are incorporated into SMC after 24 h of incubation
at 0.1 mg/mL of concentration. As shown in Fig. 7, the
MNPs are clearly visible and distinct from the cellular
matter because of their high electron density. The particles
or their aggregates are distributed outside, on the surface of
Fig. 7 The thin-section TEM
images of SMC incubated with
0.1 mg/mL of DMSA-MNPs for
24 h. a Control SMC 9 10 K, b
SMC incubated with DMSA-
MNPs 9 10 K, and c SMC
incubated with DMSA-
MNPs 9 35 K. Arrows denote
the MNPs or their aggregates
Fig. 8 The TNF-a level in the supernate of SMC incubated with
DMSA-MNPs. The level is expressed with optical density of ELISA
results. a SMC was incubated with DMEM containing the indicated
concentration of DMSA-MNPs for 24 h. b SMC was incubated with
DMEM containing 0.1 mg/mL DMSA-MNPs for the indicated
incubation time
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123the membrane and inside of cell. We infer that the nano-
particles or their aggregates are absorbed on the membrane
due to their small size effect, and incorporated by endo-
cytosis vesicles through the deformation of the membrane,
and then dispersed in cytoplasm of SMC. We can observe
that the particles are swallowed by lysosome in cytoplasm
from Fig. 7b and c. However, the fate of MNPs during
cellular degradation is a key and unknown question.
TNF-a Level
Tumor necrosis factor a is a polypeptide cytokine that
promotes antitumor and immune responses [33], also called
pro-inﬂammatory cytokine. For SMC, TNF-a is released
from cells when the cells are damaged, and then the free
TNF-a will promote the inﬂammatory damage of cells
inversely. The supernate of SMC incubated with DMSA-
MNPs under the same experiment conditions was collected
and mixed. Then, the TNF-a was assayed by ELISA. The
results were shown in Fig. 8 The level of TNF-a is normal
compared with control, which means that DMSA-MNPs
did not elicit the production of the pro-inﬂammatory
cytokine TNF-a. Therefore, DMSA-MNPs cannot lead to
SMC inﬂammatory damage in vitro. The other two types of
MNPs show the same results (the data not shown). In
conclusion, the three types of MNPs display the biocom-
patibility with SMC. Using our chosen endpoints, SMC do
not damaged by the MNPs.
SMC Viability/Cytotoxicity Studies
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide) assay is a simple nonradioactive colori-
metric assay to measure cell cytotoxicity, proliferation, or
viability [34]. The active SMC is able to convert this dye
into a water-insoluble dark-blue formazan by reductive
cleavage of the tetrazolium ring [35]. Formazan crystals,
then, was dissolved in acidiﬁcation isopropanol by mea-
suring the absorbance of the solution at 570 nm, and the
resultant value is related to the number of living cells.
The viability of SMC is apparently decreased with the
increasing of the concentration and incubation time of
DMSA-MNPs compared with the control, as shown in
Fig. 9a and b. The data were analyzed by statistical method
and the result indicates there is statistical difference when
the concentration of magnetic nanoparticles is more than
0.1 mg/mL (p\0.05). Here, the viability means the
activity, the cytotoxicity and the number of SMC. The
decrease of viability may be resulted from the damage,
proliferation inhibition of SMC by DMSA-MNPs.
Fig. 9 The viability of SMC
incubated with MNPs. All
values are expressed as the
mean ± (SD) of three
experiments, each performed in
octuple. Control columns mean
that SMC was incubated with
only DMEM. a SMC was
incubated with DMEM
containing the indicated
concentration of DMSA-MNPs
for 24 h. b SMC was incubated
with DMEM containing 0.1 mg/
mL DMSA-MNPs for the
indicated incubation time. c
SMC was incubated with
DMEM containing 0.1 mg/mL
indicated MNPs for 24 h
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123Considering the TNF-a level, we can infer that the decrease
of viability is caused from proliferation inhibition of SMC
by DMSA-MNPs.
However, the viability of SMC has not shown obviously
statistical difference when incubated with three types of
MNPs at the same concentration (0.1 mg/mL) and incu-
bation time (24 h), which demonstrates that the properties
of MNPs (used in the experiments) hardly have effect on
the viability of SMC. The data are shown in Fig. 9c.
Conclusions
The work has focused on the effect of iron oxide magnetic
nanoparticles on SMCs. The magnetic nanoparticles
(DMSA-MNPs APTS-MNPs, and GLU-MNPs) have the
same crystal structure, magnetic properties, and size dis-
tribution. Cellular uptake of MNPs displays the dose, the
incubation time, and surface property dependent patterns.
Through the thin section TEM images, we observe that
DMSA-MNPs are incorporated into the lysosome of SMC.
The MNPs have no inﬂammation impact, but decrease the
viability of SMC. The other questions about metabolism
and other impacts will be the next subject of further
studies.
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